Description
What It Is
VA-3R is Vantage’s catalog name for retatrutide, a triple receptor agonist with activity at the GLP-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple mechanism distinguishes it from mono- and dual-incretin agonists, adding glucagon receptor activation to the GLP-1R/GIPR profile. The addition of GCGR agonism is studied for its effects on hepatic glucose production, lipid oxidation, and energy expenditure in preclinical models.
Supplied lyophilized at 10mg per vial.
Who It’s For
Researchers studying triple-receptor agonism pharmacology, comparative incretin biology (mono vs. dual vs. triple agonist), hepatic glucose regulation, and multi-pathway metabolic signaling. The triple-receptor profile makes VA-3R a mechanistically distinct tool compound from VA-1S and VA-2T.
Key Research Applications
- Triple GLP-1R/GIPR/GCGR co-activation and downstream signaling
- Comparative pharmacology: mono vs. dual vs. triple incretin agonism
- Hepatic glucose production and glucagon receptor biology
- Energy expenditure and lipid oxidation in metabolic models
- Pancreatic islet biology under combined incretin and glucagon receptor stimulation
Handling & Reconstitution
Store lyophilized VA-3R (retatrutide) at 2 to 8°C, protected from light and moisture. Reconstitute with a suitable sterile solvent. The compound is water-soluble. Once reconstituted, store at 4°C and use within 28 days. Aliquot to avoid repeated freeze-thaw cycles.
Disclaimer: For research use only. Not for human or veterinary use. Not approved by the FDA. 21+
Full reference record, including verified molecular data and the batch COA policy: Retatrutide.
Reviews
There are no reviews yet.